Regenerative Medicines Provisions Of Cures Act A Top Priority For CBER

CBER Director Peter Marks says center will mobilize necessary resources to make sure these provisions are implemented; Marks also offered comments in opposition to 'right-to-try' legislation.

FDA entrance sign 2016

Regardless of the uncertainty surrounding the upcoming budget and user fee negotiations, the Center for Biologics Evaluation and Research (CBER) will make the implementation of the 21st Century Cures Act's regenerative medicines provisions a major priority, center Director Peter Marks says.

"At the moment, we are reasonably well-resourced … I think just as Dr. [Janet] Woodcock in CDER was able to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Cell & Gene Therapies

More from Advanced Technologies